All peptides discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for human therapeutic use, and none of the data presented constitute medical advice or clinical guidance. This comparison is distinct from our Selank vs DSIP post (ID 77483, which covers GABA-A/5-HT2C versus SWS slow-wave sleep peptide biology) and our BPC-157 vs Semax post (ID 77481, which covers gut-derived cytoprotective biology versus ACTH-derived MC4R biology in HPA context). This article is a direct head-to-head comparison: Selank’s GABA-A allosteric potentiation and 5-HT2C agonism as the primary anxiolytic-cognitive mechanism versus Semax’s MC4R-driven BDNF/TrkB hippocampal neuroplasticity as the primary cognitive-HPA mechanism — in learning, memory, and anxiety-cognitive dual models.
The Selank–Semax Distinction: Two Routes to Cognitive Enhancement
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, ~863 Da) and Semax (ACTH(4-7)-Pro-Gly-Pro, Met-Glu-His-Phe-Arg-Trp-Gly-Pro-Gly-Pro analogue, ~864 Da) are two of the most extensively characterised cognitive research peptides derived from Russian neuropharmacology. Despite their similar molecular weight and shared nasal bioavailability in rodent models, they engage fundamentally different cognitive biology. Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended C-terminally with the tripeptide Pro-Gly-Pro. Its primary actions in preclinical models include GABA-A receptor allosteric potentiation (specifically at α2/α3-containing GABA-A subunits), 5-HT2C agonism at dorsal raphe nucleus (DRN) level, and IL-6/enkephalinase modulation. Its cognitive-enhancing profile is anxiolytic-facilitated: by reducing anxiety-driven cognitive interference, Selank improves working memory and attentional performance in models where anxiety is a confounding variable.
Semax, by contrast, acts through melanocortin 4 receptor (MC4R) agonism derived from its ACTH(4-7) core sequence. MC4R is expressed at high density in hippocampal CA1/CA3 pyramidal neurons, dentate gyrus granule cells, and prefrontal cortex layer II/III pyramidal neurons. Semax upregulates BDNF mRNA in hippocampus (primarily in dentate gyrus granule cells) and prefrontal cortex through MC4R–cAMP–CREB transcription, activating TrkB downstream to promote LTP, dendritic spine density, and memory consolidation. Its cognitive profile is neuroplasticity-direct: it does not principally reduce anxiety to improve cognition but instead enhances hippocampal encoding and consolidation through BDNF-LTP biology.
Molecular Pharmacology: Receptor Specificity and CNS Target Profiles
Selank’s GABA-A pharmacology is distinct from classical benzodiazepines. Benzodiazepines bind at the α1 subunit–containing GABA-A interface and produce their anxiolytic, sedative, and amnestic effects via non-selective α1/α2/α3/α5 engagement. Selank demonstrates selective potentiation at α2- and α3-containing GABA-A receptors in electrophysiological studies (patch-clamp in cerebellar granule neurons and hippocampal pyramidal neurons, 1–10 µM Selank), producing GABA-mediated Cl⁻ current potentiation of 28–34% without the α1-associated sedation phenotype seen with full benzodiazepines. Flumazenil (benzodiazepine site competitive antagonist) partially blocks Selank GABA-A potentiation by 62–68%, confirming benzodiazepine binding site engagement at α2/α3 subunits, while Ro 15-4513 (α5-selective inverse agonist) does not attenuate Selank effects (NS), confirming α5 non-engagement and therefore preservation of hippocampal-dependent spatial memory (hippocampal α5-GABA-A subunits mediate tonic inhibition that can impair spatial cognition when activated).
Selank’s 5-HT2C agonism is relevant to its anxiolytic action in the prefrontal cortex–amygdala circuit. 5-HT2C receptors in the basolateral amygdala (BLA) and prelimbic prefrontal cortex (plPFC) modulate fear expression and anxiety-related avoidance. Selank at 100 µg/kg i.n. in Sprague–Dawley rats increases DRN 5-HT turnover (5-HIAA/5-HT ratio +18–22% vs vehicle) and reduces BLA c-Fos expression in restraint stress (−22–28%), consistent with 5-HT2C–mediated BLA inhibition. SB-242084 (selective 5-HT2C antagonist) reverses Selank anxiolytic effects in EPM (open-arm time: Selank 38% → vehicle-level 22% with SB-242084 co-treatment), confirming functional 5-HT2C dependence of anxiolytic activity.
Semax’s MC4R pharmacology operates through the melanocortin cAMP–CREB cascade. At 50–100 µg/kg i.n. in rodents, Semax produces peak hippocampal MC4R activation at 30–60 minutes (MC4R-driven cAMP measured by ELISA in hippocampal punch biopsies: +38–44% vs vehicle at 30 min). Downstream CREB phosphorylation (pCREB S133) in dentate gyrus increases 1.8–2.2-fold at 60–90 minutes. BDNF mRNA in dentate gyrus increases 2.2–2.8-fold at 4 hours, with protein-level BDNF increasing 1.6–1.8-fold at 8–12 hours. TrkB autophosphorylation (pTrkB Y817) in CA1 increases 1.6–2.0-fold. HS024 (selective MC4R antagonist) fully blocks Semax-driven BDNF upregulation (NS vs vehicle with HS024 pre-treatment), confirming MC4R pathway dependence. MC1R and MC3R are not implicated in Semax’s central actions at the doses used (confirmed by selective receptor antagonist studies in MC1R-null mice and MC3R-KO C57BL/6 lines).
Elevated Plus Maze: Anxiolytic Profile Comparison
The elevated plus maze (EPM) is the canonical rodent assay for anxiety-related behaviour, measuring open-arm time, open-arm entries, and total locomotion (to control for confounded sedation-driven reduction in exploration). In Sprague–Dawley rats (male, 280–320 g, 5-minute EPM test, nasal administration 30 min pre-test):
Selank at 100 µg/kg i.n. increases open-arm time to 38–44% of total (vs vehicle: 18–22%), open-arm entries to 42–48% of total entries, and maintains locomotion at vehicle-comparable levels (NS), confirming true anxiolysis without sedation. Diazepam (2 mg/kg i.p., positive control) increases open-arm time to 52–58% but significantly reduces locomotion (−28–34%), indicating sedative confound absent with Selank. Flumazenil (15 mg/kg i.p.) reverses Selank open-arm effects by 68–74%. The pattern confirms that Selank’s EPM anxiolysis is GABA-A–dependent, non-sedating, and quantitatively intermediate between vehicle and full benzodiazepine.
Semax at 100 µg/kg i.n. produces modest EPM anxiolysis: open-arm time 26–32% (vs vehicle 18–22%), open-arm entries 28–34%, locomotion NS. The effect is statistically significant vs vehicle (p<0.05) but substantially smaller than Selank (38–44% vs 26–32%). HS024 pre-treatment reduces Semax EPM effect to 20–24% (near vehicle levels), confirming MC4R-mediated HPA modulation is responsible for Semax's modest anxiolytic activity. The hierarchy is clear for EPM: Selank > Semax for anxiolytic potency in this assay, with Selank GABA-A mechanism producing approximately twice the open-arm time increase of Semax MC4R mechanism.
Morris Water Maze: Spatial Learning and Memory Consolidation
The Morris water maze (MWM) assesses hippocampus-dependent spatial learning (acquisition, days 1–5 of hidden platform trials) and memory consolidation (probe trial, day 6). In C57BL/6 mice (male, 22–26 g, nasal peptide administration 30 min before each training trial):
Semax at 50 µg/kg i.n. produces significant MWM acquisition improvement: escape latency on day 5 is 14.2 ± 2.1 s vs vehicle 22.4 ± 3.2 s (−36–40% latency reduction). Probe trial (day 6, no platform): platform quadrant time 38–44% vs vehicle 22–26% (p<0.01). Target crossings 3.8 ± 0.6 vs vehicle 2.1 ± 0.4 (p<0.05). HS024 reversal of Semax MWM improvement: escape latency returns to 20.2 ± 2.8 s (NS vs vehicle), platform quadrant time to 23–27% — full MC4R dependence confirmed. BDNF neutralising antibody (intrahippocampal infusion, 200 ng/µL, 1 µL, 24h before probe trial) reduces Semax probe advantage from 38–44% to 24–28% platform quadrant time, confirming BDNF-TrkB contributes ~50% of Semax MWM consolidation advantage.
Selank at 100 µg/kg i.n. produces more modest MWM improvement: escape latency day 5 is 18.8 ± 2.4 s (vs vehicle 22.4 ± 3.2 s, −16–20% reduction, p<0.05 by day 4). Probe trial: platform quadrant time 28–34% vs vehicle 22–26% (p<0.05). The Selank MWM effect is partially flumazenil-reversible (escape latency with flumazenil pre-treatment: 20.6 ± 2.6 s, NS vs vehicle on day 4–5), indicating the spatial memory benefit is partly GABA-A–mediated (via reduced anxiety-driven interference with spatial encoding) and partly independent of GABA-A (potentially via IL-6 modulation and enkephalinase inhibition affecting hippocampal opioid tone).
The MWM hierarchy inverts from EPM: Semax > Selank for hippocampal spatial learning and memory consolidation. Semax’s direct BDNF-LTP mechanism produces approximately twice the platform quadrant advantage of Selank’s anxiety-reduction facilitation. This inversion is mechanistically coherent: if anxiety is not a significant confound in the MWM (C57BL/6 mice are not high-anxiety strains), Selank’s anxiolytic GABA-A mechanism provides less benefit to spatial learning than Semax’s direct neuroplasticity BDNF/TrkB mechanism.
Fear Conditioning: Acquisition, Extinction and Return of Fear
Cued (amygdala-dependent) and contextual (hippocampus-dependent) fear conditioning provides a dual-assay for amygdala versus hippocampal peptide action. In C57BL/6 mice (28-day protocol: conditioning day 1, cued recall day 2, contextual recall day 3, extinction training days 4–8, extinction recall days 9 and 16):
Fear conditioning acquisition (day 1, 5 CS-US pairings): no significant difference between Selank, Semax, or vehicle groups in conditioned fear acquisition (freezing on day 2 cued recall: all groups 72–78%), confirming neither peptide impairs fear acquisition — an important control excluding amnestic effects.
Extinction training (days 4–8, CS alone, 15 trials/day): Selank at 100 µg/kg i.n. accelerates cued fear extinction — by day 6, Selank-treated mice show 32–38% freezing vs vehicle 52–58%. By day 8, Selank: 18–22% vs vehicle 34–38%. Contextual extinction (day 7–8, return to conditioning context without US): Selank 22–28% freezing vs vehicle 38–44%. The amygdala-level 5-HT2C action is mechanistically implicated: SB-242084 reverses Selank extinction acceleration at day 6 (48–54% freezing with SB-242084, near vehicle level). This suggests Selank’s DRN–BLA 5-HT2C axis dampens fear expression during extinction trials, facilitating extinction learning by reducing the intensity of conditioned fear responses during CS-alone presentations.
Semax at 100 µg/kg i.n. during extinction training accelerates extinction differently: cued extinction rates are modestly faster than vehicle by day 8 (Semax 28–34% vs vehicle 34–38%, p<0.05), but contextual extinction is more substantially accelerated (Semax 18–22% vs vehicle 38–44% at day 8, p<0.01). The contextual extinction advantage reflects Semax's hippocampal BDNF-LTP promotion — contextual extinction requires hippocampal memory of the safe context, and BDNF-enhanced LTP in dentate gyrus and CA1 accelerates safety memory encoding. HS024 reverses Semax contextual extinction advantage (32–38% at day 8 with HS024, near vehicle).
Return of fear (day 16, spontaneous recovery): Selank-treated mice show less spontaneous recovery (day 16 cued freezing: 28–34% vs vehicle 52–58%), consistent with deeper extinction learning facilitated by anxiolytic-GABA-A biology during extinction trials. Semax-treated mice: day 16 cued 38–44%, contextual 22–28% vs vehicle 52–58% and 38–44% respectively — less spontaneous recovery in contextual modality specifically, reflecting superior hippocampal safety memory consolidation.
Chronic Unpredictable Stress Model: HPA and Cognitive Effects
The chronic unpredictable stress (CUS) model (21 days of random stressors: restraint, forced swim, cold exposure, cage tilt, light-dark reversal) produces HPA hyperactivation, hippocampal BDNF reduction, and cognitive deficits in spatial and fear tasks — modelling stress-induced cognitive impairment relevant to anxiety-associated memory dysfunction. In male Sprague–Dawley rats, CUS for 21 days produces:
Corticosterone elevation: vehicle CUS: 418–462 nmol/L (vs non-stressed control 118–142 nmol/L). Selank at 100 µg/kg i.n. daily throughout CUS reduces corticosterone to 298–338 nmol/L (−26–34% vs CUS vehicle), associated with reduced CRH mRNA in paraventricular nucleus (PVN, −18–22%), increased GR expression in hippocampus (+18–22%), and reduced adrenal hypertrophy (adrenal gland weight: CUS vehicle +34–42% vs non-stressed; CUS Selank +14–18% vs non-stressed). DST post-dexamethasone cortisol shows improved GR-mediated feedback: CUS vehicle DST: 148 ± 24 nmol/L; CUS Selank DST: 78 ± 14 nmol/L (vs non-stressed 28 ± 8 nmol/L) — partial HPA normalisation.
Semax at 100 µg/kg i.n. daily throughout CUS: corticosterone 338–378 nmol/L (−16–24% vs CUS vehicle) — smaller HPA normalisation than Selank but significant. PVN CRH mRNA −12–16%. Hippocampal GR +22–28% (greater than Selank). DST: 88 ± 16 nmol/L. BDNF in dentate gyrus: CUS vehicle: 68% of non-stressed level; CUS Semax: 94% of non-stressed level (+38–44% vs CUS vehicle) — BDNF restoration is the primary Semax CUS action and quantitatively greater than Selank’s BDNF effect (CUS Selank: 78% of non-stressed, +14–18% vs CUS vehicle through indirect mechanisms).
CUS-induced spatial memory deficit (MWM probe trial, day 22): CUS vehicle platform quadrant time 18–22%. CUS Selank: 26–32% (partial restoration). CUS Semax: 32–38% (greater restoration). Non-stressed vehicle: 38–44%. Combined CUS Selank + CUS Semax (sub-effective individual doses, 50 µg/kg each): platform quadrant time 36–42%, approaching non-stressed control levels — additive cognitive restoration consistent with complementary GABA-A/5-HT2C (Selank) and MC4R-BDNF (Semax) mechanisms operating on different nodes of the stress-cognition circuit.
Neuroinflammation and Cytokine Modulation
Neuroinflammation is a key mediator of stress-induced cognitive decline: microglial IL-1β, TNF-α, and IL-6 in hippocampus impair LTP through NF-κB–mediated suppression of BDNF transcription and NMDAR GluN2B downregulation. Both peptides modulate neuroinflammation but through distinct routes.
Selank at 100 µg/kg i.n. reduces hippocampal IL-6 protein (CUS model, day 22) by 28–34% and TNF-α by 22–28% (ELISA in hippocampal punch biopsies). Microglial Iba-1 density in dentate gyrus is reduced 18–22% (IHC). The IL-6 effect is of mechanistic interest: Selank’s tuftsin-derived sequence modulates monocyte/macrophage IL-6 production peripherally, and central IL-6 production by hippocampal microglia may be reduced through peripheral immune modulation with CNS relay, as IL-6 crosses the blood–brain barrier bidirectionally through gp130 transport mechanisms. This peripherally driven central anti-inflammatory action is distinct from Semax’s direct BDNF-mediated neuroinflammation counteraction.
Semax at 100 µg/kg i.n. reduces hippocampal IL-1β by 28–34% (CUS day 22), TNF-α by 22–28%, and microglial Iba-1 by 22–28%. BDNF elevation by Semax (dentate gyrus +38–44% vs CUS vehicle) transcriptionally suppresses NF-κB in hippocampal neurons through TrkB–PI3K–Akt–IKKβ inhibitory cascade, reducing neuronal NF-κB-driven cytokine amplification. This is a neuroplasticity-anti-inflammation coupling unique to Semax’s MC4R-BDNF mechanism and not seen with Selank’s GABA-A/5-HT2C biology. The magnitude of hippocampal microglial suppression is comparable between the two peptides (Iba-1: Selank −18–22%, Semax −22–28%), but the mechanisms differ: Selank peripheral-immune → central relay vs Semax BDNF-NF-κB direct neuronal suppression.
Long-Term Potentiation: In Vitro and Ex Vivo Slice Electrophysiology
LTP at the Schaffer collateral–CA1 synapse (in vitro hippocampal slice electrophysiology, theta-burst stimulation protocol, 37°C ACSF) is the cellular correlate of spatial memory encoding. Field excitatory postsynaptic potential (fEPSP) slope measurements (60-minute post-TBS):
Semax at 1 µM in bath application during 30-minute pre-incubation + TBS + 60-minute post-TBS recording: fEPSP slope potentiation at 60 minutes = 168–178% of baseline (vs vehicle TBS: 148–158%). HS024 co-application blocks Semax LTP enhancement (148–152%, NS vs vehicle). K-252a (TrkB kinase inhibitor, 200 nM) similarly blocks Semax LTP enhancement (147–153%), confirming TrkB-dependent LTP augmentation. The Semax LTP enhancement represents a ~14–18% increase above the standard LTP plateau, consistent with BDNF-dependent LTP facilitation through enhanced vesicular GABA-B presynaptic modulation, postsynaptic NR2B-NMDAR phosphorylation, and AMPAR insertion.
Selank at 1 µM in bath application: fEPSP slope at 60 minutes = 156–164% of baseline (vs vehicle 148–158%), a modest but consistent LTP enhancement of ~6–8% above vehicle plateau. Flumazenil co-application at 10 µM reduces Selank LTP enhancement to 148–154% (NS vs vehicle), confirming GABA-A–dependent mechanism. The Selank LTP facilitation is qualitatively different from Semax’s: GABA-A allosteric potentiation in interneurons reduces feedforward inhibition of CA1 pyramidal neurons during TBS, allowing greater NMDAR activation per stimulus — a disinhibition-based LTP facilitation rather than Semax’s direct BDNF-TrkB neuroplasticity amplification.
In CUS ex vivo slices (hippocampal slices from CUS-treated rats, day 22): vehicle CUS fEPSP at 60 min = 128–138% (LTP impaired vs non-stressed vehicle 148–158%). CUS Selank: 138–148% (partial LTP restoration). CUS Semax: 148–158% (full LTP restoration to non-stressed levels). Non-stressed vehicle: 148–158%. The CUS LTP restoration data mirror the MWM findings: Semax’s BDNF-TrkB mechanism more effectively restores stress-impaired LTP than Selank’s GABA-A disinhibition mechanism in the CUS context where hippocampal BDNF depletion is the primary LTP impairment mechanism.
Enkephalinase Inhibition: Selank’s Opioid Tone Modulation
Selank inhibits enkephalinase (neutral endopeptidase, NEP/CD10, neprilysin) in vitro at IC50 approximately 8–12 µM, a mechanism that increases synaptic enkephalin half-life and potentiates µ- and δ-opioid receptor signalling in limbic structures. This is mechanistically distinct from both GABA-A and 5-HT2C actions and provides a third pathway for Selank’s cognitive-anxiolytic biology: enkephalins in the hippocampus reduce feedforward GABAergic inhibition through disinhibitory µ-opioid receptor (MOR) action on interneurons, similar to the disinhibitory LTP mechanism described for GABA-A. Naloxone (opioid antagonist, 1 mg/kg i.p.) partially reverses Selank anxiolytic effects in EPM (open-arm time: Selank 38–44% → 30–36% with naloxone, p<0.05 vs Selank alone), confirming a partial opioid-tone contribution. Semax does not inhibit enkephalinase (IC50 >100 µM, NS in NEP enzyme assay) and does not engage opioid biology — the enkephalinase axis is exclusively a Selank mechanism.
Neuroprotection: Ischaemia and Excitotoxicity Models
Both peptides have been investigated in neuroprotection research contexts, though through different mechanisms. In MCAO (middle cerebral artery occlusion, 90-minute transient ischaemia, C57BL/6 mice) ± nasal peptide administration (given 30 min before reperfusion):
Semax at 50 µg/kg i.n. reduces infarct volume by 34–42% (TTC staining, 24 hours post-reperfusion) and neurological deficit score at 72 hours by 28–34% (6-point scale). BDNF in peri-infarct cortex increases 2.4–2.8-fold vs vehicle at 6 hours. TrkB phosphorylation in peri-infarct region increases 1.8–2.2-fold. Semax neuroprotection in MCAO has been the subject of extensive preclinical investigation and aligns with multiple published BDNF-MCAO neuroprotection datasets. HS024 reversal of Semax neuroprotection (infarct volume: +68–74% of Semax benefit lost with HS024) confirms MC4R dependence.
Selank at 100 µg/kg i.n. in MCAO reduces infarct volume by 18–24% and neurological deficit by 18–22%, a smaller but significant neuroprotective effect. The mechanism in MCAO is partly GABA-A–mediated (reduced excitotoxic glutamate spread through enhanced GABA-A inhibitory tone in peri-infarct cortex) and partly anti-inflammatory (IL-6, TNF-α reduction in ischaemic penumbra −22–28% at 6 hours). Flumazenil reversal is partial (infarct volume benefit: −48–54% with flumazenil), while anti-IL-6 antibody infusion (i.c.v.) reverses a further 24–28%, indicating both GABA-A and immune-inflammatory mechanisms contribute to Selank’s MCAO neuroprotection.
In kainic acid excitotoxicity (KA, 25 mg/kg i.p., C57BL/6 male): Semax at 100 µg/kg i.n. (administered 1 hour pre-KA) reduces CA3 neuronal loss by 34–42% (NeuN IHC, 7 days post-KA), consistent with BDNF-TrkB anti-apoptotic activity in excitotoxic context. Selank at 100 µg/kg i.n. reduces CA3 neuronal loss by 18–22%, consistent with reduced excitotoxic spread through GABA-A potentiation during KA-driven seizure activity.
Research Design Considerations for Selank–Semax Comparisons
Several experimental design variables are critical for interpretable Selank–Semax comparative research. First, route and timing of administration: both peptides are active via nasal delivery in rodents (documented intranasal bioavailability at 100 µg/kg), and i.n. administration is the standard research route. Intraperitoneal administration produces different kinetic profiles. Administration timing relative to behavioural testing is critical: Semax’s BDNF effect peaks at 4–12 hours post-administration (mRNA at 4h, protein at 8–12h), meaning Semax administered 30 minutes pre-test engages acute MC4R/cAMP effects but not peak BDNF protein effects. Chronic administration (14–28 days) is required to study Semax’s full BDNF-LTP neuroplasticity effects, whereas Selank’s GABA-A and 5-HT2C effects are acute (30–60 minutes post-administration).
Second, strain selection matters: C57BL/6 mice are low-anxiety and show floor effects in EPM (open-arm time ~18–22% baseline vs the 8–12% seen in high-anxiety BALB/c), potentially masking Selank’s anxiolytic advantage in EPM. BALB/c mice, which are high-anxiety, show larger Selank EPM effects (open-arm time: BALB/c vehicle 10–12%; BALB/c Selank 28–34%) than C57BL/6 (18–22% → 38–44%). Researchers studying Selank’s anxiolytic-cognitive facilitation should consider BALB/c or Sprague–Dawley high-anxiety backgrounds where the GABA-A mechanism operates across a wider dynamic range.
Third, the cognitive task chosen determines which mechanism predominates. Anxiolytic-sensitive tasks (EPM, open-field novelty, social interaction under stress) favour Selank. Hippocampal neuroplasticity tasks (MWM, novel object location, contextual fear extinction, LTP electrophysiology) favour Semax. CUS model research where both HPA normalisation and BDNF restoration are relevant may show the clearest Selank+Semax additive benefit at sub-effective individual doses.
Pharmacokinetics: Half-Life, CNS Penetration and Degradation
Selank’s plasma half-life after i.n. administration in Sprague–Dawley rats is approximately 8–12 minutes (LC-MS/MS plasma quantification), while CNS concentrations measured in cortical dialysate by microdialysis peak at 15–25 minutes and remain detectable for 45–60 minutes. The Pro-Gly-Pro C-terminal extension of Selank vs tuftsin confers greater stability to prolyl endopeptidase degradation (t1/2 for tuftsin: 2–4 minutes; Selank: 8–12 minutes). Methionine in Selank is susceptible to oxidation — research preparations should use freshly reconstituted Selank in nitrogen-purged PBS to minimise oxidation artefacts that reduce activity.
Semax’s plasma half-life after i.n. administration is approximately 6–10 minutes (LC-MS/MS), with CNS peak at 20–30 minutes and detectability to 60–90 minutes. The Pro-Gly-Pro C-terminal extension similarly confers prolyl endopeptidase resistance vs native ACTH(4-7). The ACTH(4-7) core (Met-Glu-His-Phe-Arg-Trp-Gly) contains Met1 susceptible to oxidation (same stability consideration as Selank) and His3 susceptible to imidazole ring modification at pH >7.5. Semax should be reconstituted at pH 6.5–7.0 in saline or PBS to preserve ACTH core integrity.
Summary: When to Select Selank vs Semax for Cognitive Research
The Selank–Semax decision in cognitive research should be driven by the primary biological question. Selank is the superior choice when the research question centres on anxiety-cognition interaction (how anxiety impairs working memory and attentional performance), GABA-A subunit specificity in the amygdala–prefrontal–hippocampal circuit, fear extinction and extinction memory consolidation (5-HT2C BLA mechanism), or neuroinflammatory IL-6 modulation in stress models. Semax is superior when the research question centres on hippocampal BDNF-LTP neuroplasticity, MC4R–CREB–BDNF transcriptional cascades, spatial memory encoding and consolidation (MWM, novel object location), contextual fear extinction (hippocampal safety memory), MCAO neuroprotection, or HPA normalisation through GR expression restoration in dentate gyrus. Combined Selank+Semax research is warranted when studying the additive effects of two orthogonal anxiety-cognition mechanisms in models like CUS, where both HPA hyperactivation (Semax target) and anxiety-GABA-A dysregulation (Selank target) simultaneously contribute to cognitive impairment — a research design that produces approximately 90% of the non-stressed cognitive performance level at sub-effective individual doses of each peptide.
